| [1] |
Dess RT, Morgan TM, Nguyen PL, et al. Adjuvant versus early salvage radiation therapy following radical prostatectomy for men with localized prostate cancer[J]. Curr Urol Rep, 2017, 18(7): 55.
|
| [2] |
Vrieling C, Assele SY, Moser L, et al. The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy[J]. Eur J Cancer, 2021, 155: 28-37.
|
| [3] |
Abderrahman B, Jordan VC. Telling details of breast-cancer recurrence[J]. Nature, 2018, 553(7687): 155.
|
| [4] |
Duffy M, Evoy D, Mcdermott E. CA 15-3: uses and limitation as a biomarker for breast cancer[J]. Clin Chim Acta, 2010，411(23-24)：1869-1874.
|
| [5] |
Puglisi R, Bellenghi M, Pontecorvi G, et al. SCD5 restored expression favors differentiation and epithelial-mesenchymal reversion in advanced melanoma[J]. Oncotarget, 2018, 9(7): 7567-7581.
|
| [6] |
Pandey V, Jain P, Chatterjee S, et al. Variants in exon 2 of MED12 gene causes uterine leiomyoma’s through over-expression of MMP-9 of ECM pathway[J]. Mutat Res, 2023, 828: 111 839.
|
| [7] |
Xu S, Liu D, Qin Z, et al. Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer[J]. Aging (Albany NY), 2023, 15(24): 15 134-15 160.
|
| [8] |
Barman B, Thakur MK. Neuropsin promotes hippocampal synaptogenesis by regulating the expression and cleavage of L1CAM[J]. J Cell Sci, 2024，137(3)：jcs261422.
|
| [9] |
Shan J, Yuan L, Xiao Q, et al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells[J]. Cancer Res, 2002, 62(1): 290-294.
|
| [10] |
Mirza Z. Integrated high-throughput transcriptomic data identifies survivin as a potential breast cancer therapeutic biomarker[J]. Curr Med Chem, 2024, 31(5): 649-663.
|
| [11] |
Ndiaye R, Diop JPD, Dem A, et al. Genetic contribution of breast cancer genes in women of black African origin[J]. Front Genet, 2023, 14: 1 302 645.
|
| [12] |
Diehl F, Schmidt K, Choti M, et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008, 14(9): 985-990.
|
| [13] |
Roshan-Moniri M, Hsing M, Butler M, et al. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers[J]. Cancer Treat Rev, 2014, 40(10): 1137-1152.
|
| [14] |
Di Masi A, De Marinis E, Ascenzi P, et al. Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects[J]. Mol Aspects Med, 2009, 30(5): 297-343.
|
| [15] |
Fuentes-Prior P, Rojas A, Hagler A, et al. Diversity of quaternary structures regulates nuclear receptor activities[J]. Trends Biochem Sci, 2019, 44(1): 2-6.
|
| [16] |
Li Q, Ke N, Sundaram R, et al. NR4A1, 2, 3--an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis[J]. Histol Histopathol, 2006, 21(5): 533-540.
|
| [17] |
Llopis S, Singleton B, Duplessis T, et al. Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer[J]. BMC Cancer, 2013, 13: 139.
|
| [18] |
Maira M, Martens C, Philips A, et al. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation[J]. Mol Cell Biol, 1999, 19(11): 7549-7557.
|
| [19] |
Wilson T, Fahrner T, Milbrandt J. The orphan receptors NGFI-B and steroidogenic factor 1 establish monomer binding as a third paradigm of nuclear receptor-DNA interaction[J]. Mol Cell Biol, 1993, 13(9): 5794-5804.
|
| [20] |
Mohan H, Aherne C, Rogers A, et al. Molecular pathways: the role of NR4A orphan nuclear receptors in cancer[J]. Clin Cancer Res, 2012, 18(12): 3223-3228.
|
| [21] |
Safe S, Karki K. The paradoxical roles of orphan nuclear receptor 4A (NR4A) in cancer[J]. Mol Cancer Res, 2021, 19(2): 180-191.
|
| [22] |
Wilson T, Fahrner T, Johnston M, et al. Identification of the DNA binding site for NGFI-B by genetic selection in yeast[J]. Science, 1991, 252(5010): 1296-1300.
|
| [23] |
Zhang T, Wang P, Ren H, et al. NGFI-B nuclear orphan receptor Nurr1 interacts with p53 and suppresses its transcriptional activity[J]. Mol Cancer Res, 2009, 7(8): 1408-1415.
|
| [24] |
Inamoto T, Czerniak B, Dinney C, et al. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer[J]. Cancer, 2010, 116(2): 340-346.
|
| [25] |
Wang J, Yang J, Zou Y, et al. Orphan nuclear receptor nurr1 as a potential novel marker for progression in human prostate cancer[J]. Asian Pac J Cancer Prev, 2013, 14(3): 2023-2028.
|
| [26] |
Liu W, Cao H, Liao S, et al. Dibutyl phthalate disrupts conserved circadian rhythm in Drosophila and human cells[J]. Sci Total Environ, 2021, 783: 147038.
|
| [27] |
Karki K, Li X, Jin U, et al. Nuclear receptor 4A2 (NR4A2) is a druggable target for glioblastomas[J]. J Neurooncol, 2020, 146(1): 25-39.
|
| [28] |
Abdollahzadeh R, Azarnezhad A, Paknahad S, et al. A proposed TUSC7/miR-211/Nurr1 ceRNET might potentially be disturbed by a cer-SNP rs2615499 in breast cancer[J]. Biochem Genet, 2022, 60(6): 2200-2225.
|
| [29] |
Maruyama K, Tsukada T, Bandoh S, et al. Retinoic acids differentially regulate NOR-1 and its closely related orphan nuclear receptor genes in breast cancer cell line MCF-7[J]. Biochem Biophys Res Commun, 1997, 231(2): 417-420.
|
| [30] |
Jing C, Fu Y, Zhou C, et al. Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis[J]. Oncogene, 2021, 40(16): 2910-2922.
|
| [31] |
Bian X, Chen H, Yang P, et al. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation[J]. Nat Commun, 2017, 8: 14420.
|
| [32] |
Yousefi H, Fong J, Alahari S. NR4A family genes: a review of comprehensive prognostic and gene expression profile analysis in breast cancer[J]. Front Oncol, 2022, 12: 777824.
|